Developer · United States

Spinogenix, Inc.

Clinical-stage biopharmaceutical company in Los Angeles, California, developing first-in-class therapies intended to restore or regenerate synapses. Its pipeline comprises tazbentetol (SPG302), in clinical development for ALS, Alzheimer's disease and schizophrenia, and SPG601 (codabakalner) for Fragile X syndrome. Founded and led by CEO Dr. Stella Sarraf.

spinogenix.com ↗

1compound
1program
1indication
Phase 2lead asset

Phase distribution

  • Phase 21

Modality

  • Small molecule 1

Pipeline (1)

Catalysts · 1 upcoming · 1 reported

Recently reported

  • 2026-03-26pending

    TazbentetolforSchizophreniaInterim analysis

    Interim Phase 2 data (16 of 32 participants) for tazbentetol 300 mg vs placebo in schizophrenia: PANSS total -11.9 vs -5.6; PANSS positive -3.3 vs -0.1 (p=0.01); PANSS negative -1.8 vs -1.0; EEG gamma/alpha band-power changes; no severe adverse events.

    source ↗

Recent activity

  • Mar 26, 2026ReadoutTazbentetol·SchizophreniapendingInterim Phase 2 data (16 of 32 participants) for tazbentetol 300 mg vs placebo in schizophrenia: PANSS total -11.9 vs -5.6; PANSS positive -3.3 vs -0.1 (p=0.01); PANSS negative -1.8 vs -1.0; EEG gamma/alpha band-power changes; no severe adverse events.source ↗
  • Mar 11, 2026Phase changeTazbentetol·SchizophreniaPhase 2Spinogenix announced completion of enrollment of 32 adults in the Phase 2 schizophrenia study; CT.gov lists the study as Active, not recruiting.source ↗
  • Aug 1, 2024Phase changeTazbentetol·SchizophreniaPhase 2Phase 2 study NCT06442462 (SPG302-SCZ-201) started per ClinicalTrials.gov (actual start date). Spinogenix announced the launch on 2024-09-25, with sites enrolling under Australian HREC approval.source ↗

Trials recruiting · 2 recruiting of 8 sponsored

  • Phase 2/3SPG601, Placebon=248

    A Study to Investigate the Effects and Safety of SPG601 for the Treatment of Fragile X Syndrome in Male Participants

    Fragile X Syndrome (FXS)NCT07439510 ↗

  • Phase 2/3Tazbentetol, placebon=430

    Efficacy and Safety of Tazbentetol in ALS Participants

    Amyotrophic Lateral SclerosisNCT07325591 ↗

Competitive landscape

Other companies developing against Spinogenix, Inc.'s targets or indications.